Mode
Text Size
Log in / Sign up
N/A Completed N=35

Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%

Source: ClinicalTrials.gov NCT00827255 ↗
Enrolled (actual)
35
Serious AEs
—
Results posted
Jul 2012
Primary outcomePrimary: Percentage of Patients With Complete Clearing of Corneal Staining at Month 12 — 33.3 Percentage of Patients

Summary

The objective of this retrospective chart review is to evaluate the patient characteristics, treatment variations and efficacy of a second trial of Cyclosporine Ophthalmic Emulsion 0.05% therapy in chronic dry eye patients who were initially treated with Cyclosporine Ophthalmic Emulsion 0.05% but discontinued use after less than 12 weeks of treatment.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Patients With Complete Clearing of Corneal Staining at Month 12
33.3 —
SECONDARY
Schirmer's Test at Month 12
— —

Eligibility Criteria

Inclusion Criteria

  • Adults >16 years of age
  • Dry eye patients
  • Subject with history of less than 12 weeks of initial RESTASIS® treatment
  • Subject started second trial of RESTASIS® treatment prior to June 1, 2008
  • First day of second trial of RESTASIS® started ≥ 4 weeks after the last day of previous RESTASIS® treatment

Exclusion Criteria

  • Patients with Contact Lens Intolerance
  • Patients with Ocular Rosacea
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00827255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search